LEADER 01901oam  2200553   450 
001 9910716566903321
005 20210820110604.0
035   $a(CKB)5470000002522485
035   $a(OCoLC)1256571371
035   $a(OCoLC)995470000002522485
035   $a(EXLCZ)995470000002522485
100   $a20210615d2020      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aUse of neurotechnology in normal brain aging and Alzheimer's Disease (AD) and AD-related dementias (ADRD)
210  1$a[Bethesda, Md.] :$cNational Institute on Aging (NIA),$d2020.
215   $a1 online resource (ii, 25 pages)
300   $a"Final June 1, 2020."
300   $a"NIA Virtual Workshop, Division of Neuroscience, April 27, 2020."
320   $aIncludes bibliographical references.
517   $aUse of neurotechnology in normal brain aging and Alzheimer's Disease 
606   $aBrain$xAging
606   $aAlzheimer's disease$xTreatment$zUnited States
606   $aDementia$xTreatment$zUnited States
606   $aAlzheimer's disease$xTreatment$2fast
606   $aBrain$xAging$2fast
606   $aDementia$xTreatment$2fast
607   $aUnited States$2fast
615  0$aBrain$xAging.
615  0$aAlzheimer's disease$xTreatment
615  0$aDementia$xTreatment
615  7$aAlzheimer's disease$xTreatment.
615  7$aBrain$xAging.
615  7$aDementia$xTreatment.
712 02$aNational Institute on Aging.$bDivision of Neuroscience,
801  0$bGPO
801  1$bGPO
801  2$bGPO
801  2$bOCLCO
801  2$bOCLCF
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910716566903321
996   $aUse of neurotechnology in normal brain aging and Alzheimer's Disease (AD) and AD-related dementias (ADRD)$93337867
997   $aUNINA